



Gallbladder cancer with tumor thrombus in the portal vein

A case report

Xiao-Zhen Zhang, MBBS^a, Jian-Jun Tu, MD^b, Wei Chen, PhD^a, Tao Ma, PhD^a, Xue-Li Bai, MD, PhD^{a,*}, Ting-Bo Liang, MD, PhD^a

Abstract

Rationale: Gallbladder cancer (GBC) is a highly fatal malignancy. Due to its invasiveness and delayed diagnosis, many GBC patients are diagnosed with synchronous liver and hepatoduodenal ligament involvement. In our case, we report a gallbladder cancer with portal vein thrombus.

Patient concerns: A 60-year-old woman presented with persistent upper abdominal dull pain for 2 months.

Diagnoses: Ultrasound examination showed gallbladder carcinoma invading liver segment IV, and a tumor thrombus in the left and right main portal trunk. Ultrasonography and contrast-enhanced magnetic resonance imaging (MRI) showed gallbladder carcinoma with invasion of adjacent liver, and tumor thrombus in the right branch of the portal vein and intrahepatic bile duct. Abdominal computed tomography angiography (CTA) revealed no hepatic artery invasion.

Interventions: We made a decision to perform extended right lobectomy. Twenty-six days later, the patient underwent intravenous infusion port implantation for S-1 plus oxaliplatin (SOX) therapy.

Outcomes: After treatment, the patient has been doing very well and no recurrence has been found for 5 months.

Lessons: The patient with gallbladder cancer and tumor thrombus in the portal vein described in this report provides a reminder for surgeons of the importance of early diagnosis, and adequate surgical and adjuvant treatment. Multi-disciplinary treatment is significantly beneficial for the overall survival of patients with advanced GBC.

Abbreviations: CA19–9 = carbohydrate antigen 19–9, CT = computed tomography, CTA = computed tomography angiography, GBC = gallbladder cancer, HCC = hepatocellular carcinoma, ICG15 = indocyanine green retention at 15 min, MRI = magnetic resonance imaging, PVT = portal vein thrombosis, SO = S-1 plus oxaliplatin.

Keywords: gallbladder cancer, portal vein, tumor thrombus

1. Introduction

Gallbladder cancer (GBC) is a highly fatal disease, has a low response to treatment, and a poor overall prognosis, due to detection at a late stage. The 5-year survival of GBC patients is

Editor: Giovanni Tarantino.

Informed consent statement: Written informed consent was obtained from the patient.

Ethics approval: These study protocols were approved by the Medical Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine.

Conflict-of-Interest Statement: We have no conflict of interest related to case report.

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms.

Medicine (2018) 97:16(e0271)

Received: 19 December 2017 / Received in final form: 1 March 2018 / Accepted: 7 March 2018

http://dx.doi.org/10.1097/MD.000000000010271

reported to be between 0% and 10% in most reported series.^[1,2] It is the most common malignant tumor of the bile duct system and the fifth most common malignant neoplasm of the digestive tract.^[1-3] Moreover, although early GBC patients do not have specific symptoms, such as right hypochondrium pain, weight loss, and anorexia, advanced patients may present with a palpable mass, hard nodular liver, hepatomegaly, ascites, gastrointestinal, bleeding, duodenal obstruction, and jaundice which is common and an indicator of poor prognosis.^[1,4]

Portal vein thrombosis (PVT) is a frequent complication of hepatocellular carcinoma (HCC). The portal vein is very rarely involved by gallbladder tumors or thrombosis due to pressure effects. Here, we report a patient who was diagnosed with GBC and tumor thrombus in the right branch of the portal vein.

2. Case report

A 60-year-old woman presented with persistent upper abdominal dull pain for 2 months. Physical examination was unremarkable. She had been diagnosed with asymptomatic cholecystolithiasis without previous treatment. Laboratory tests revealed a slight elevation of carbohydrate antigen 19–9 (CA19–9) (53.5 U/mL; normal, <37 U/mL), and a decreased level of serum total protein (65.0 ng/L; normal, 35.0–52 ng/L). Ultrasound examination showed gallbladder carcinoma invading liver segment IV, and a tumor thrombus in the left and right main portal trunk. Ultrasonography and contrast-enhanced magnetic resonance

^a Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ^b Department of Surgery, Kaihua People's Hospital, Quzhou, China.

^{*} Correspondence: Xue-Li Bai, Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China (e-mail: shirleybai@zju.edu.cn).




Figure 1. Abdominal ultrasonography (US) (A and B) and contrast-enhanced magnetic resonance imaging (MRI) (C and D). A and B: abdominal US shows gallbladder carcinoma with invasion of adjacent liver, and tumor thrombus in the main portal vein. C and D: Contrast-enhanced MRI shows tumors in liver segment IV and the gallbladder, and tumor thrombus in the right branch of the portal vein.

imaging (MRI) showed gallbladder carcinoma with invasion of adjacent liver, and tumor thrombus in the right branch of the portal vein and intrahepatic bile duct. There was no thrombus in the extrahepatic bile duct (Fig. 1). Abdominal computed tomography angiography (CTA) revealed no hepatic artery invasion (Fig. 2). Blood examination, liver function, and chest CT were normal. Based on the examination results and multidisciplinary team discussions, we diagnosed adenocarcinoma that had originated in the gallbladder with liver invasion, and had then grown into the right portal vein trunk. According to the preoperative diagnosis and indocyanine green retention at 15 min (ICG15) (7.5%; normal, <10%), the patient underwent peritoneal adhesiolysis, cholecystectomy, choledochotomy, tissue biopsy, extended right lobectomy and lymph node dissection on

September 13, 2017. During surgery, no ascites or peritoneal dissemination was observed. Right segment and part of the segment IV were resected and the regional lymph nodes around the hilum were also dissected. Macroscopically, the tumor which was measured $8 \times 4 \times 3$ cm was located in the gallbladder, with another tumor in the right lobe of the liver close to the gallbladder bed. The size of the liver metastasis was 8×6 cm. Lymph node metastasis was not observed. In addition, tumor thrombus had grown into the right portal trunk (Fig. 3). Histological examination showed that the tumor was a moderately-differentiated adenocarcinoma with invasion of the gallbladder layer and extrahepatic connective tissues, with tumor thrombus in the portal vein (Fig. 4).

The patient was admitted to our hospital 26 days later for reexamination and adjuvant therapies. Serum CA19–9 was normal (4.7 U/mL; normal, <37 U/mL). Other laboratory tests and imaging examinations were also with in the normal range. The patient underwent intravenous infusion port implantation for S-1 plus oxaliplatin (SOX) therapy. In latest re-examination (131 days later), patient was doing very well, and SOX therapy was continued to performed. According to American Joint Committee on Cancer 8th edition Tumor Node Metastasis staging, the disease stage was defined as T4N0M0, IVA.^[7]

3. Discussion

GBC is a common and aggressive gastrointestinal neoplasm.^[5] The poor prognosis of GBC is due to the nonspecific symptoms and signs in the early stage, leading to difficulty in accurate diagnosis.^[1] GBC metastasis can result in local invasion, lymphatic metastasis, hematogenous metastasis, and implantation metastasis. In addition, the classification of lymphatic pathways from the gallbladder include: the cholecysto-retropancreatic, the cholecysto-celiac, the cholecysto-mesenteric pathway, and the hilar route that ascends directly toward the hepatic hilum. [8] Jaundice usually occurs due to obstruction of the common bile duct when the hilum is invaded. However, in our patient with GBC and tumor thrombus in the portal vein, the level of total bilirubin was normal. The reason for this is that: gallbladder cancer cells can grow into the portal vein trunk via the invasion of the liver, and not the hepatohilar bile duct. HCC with portal vein tumor thrombosis and gallbladder carcinoma with tumor thrombus in the bile duct/superior vena cava are frequently reported [9–12,4]; however, GBC with liver metastatic



Figure 2. Abdominal computed tomography angiography (CTA) (in coronal scanning image) (A) and contrast-enhanced computed tomography (CT) (in venous phase) (B). A large mass in the right anterior inferior segment to the left medial segment of the liver (arrowhead) and thrombus (arrow) in the main portal vein.




Figure 3. Appearance of the resected specimen. A: The cut surface of the resected specimen. B: Tumor thrombus from the right main portal vein. GB= gallbladder, PV=portal vein, TT=tumor thrombus.

lesion and thrombosis in the right branch of the portal vein is rare. To the best of our knowledge, only 2 cases have been reported in the literature. [13,14]

For patients with GBC complicated with PVT, preoperative diagnosis is vital to improve prognosis, especially in patients with no specific symptoms. Abdominal ultrasound is usually the first imaging method used to diagnose GBC. However, the sensitivity of ultrasound in diagnosing GC is only about 44%. [15] Serum tumor biomarkers such as CA19–9 should be determined, as the presence of elevated of CA19–9 provides strong evidence of GBC. When GBC with tumor thrombus in the portal vein is suspected, abdominal computed tomography (CT) and contrast-enhanced MRI, which are important in the evaluation of GBC, should be performed. However, MRI is not sensitive enough to detect lymph node metastasis (57%). [16] In order to improve the




Figure 4. Histological examination. The tumor was a moderately-differentiated adenocarcinoma with invasion of the gallbladder layer and extrahepatic connective tissues, with tumor thrombus in the portal vein.

sensitivity and specificity for vascular invasion, CTA, and magnetic resonance angiography (MRA) are recommended. In this case, CT and contrast-enhanced MRI correctly displayed GBC with tumor thrombus in the right branch of the portal vein, while ultrasound failed. Although endoscopic ultrasound (EUS) is a more accurate imaging examination for diagnosis of the GBC than conventional abdominal US, some studies have revealed that CT, MRI combined with CTA, or MRA were more reliable than EUS. [15,16] Thus in our case, EUS was not performed.

Surgery is considered the most effective treatment for GBC. The 5-year overall survival of patients with GBC who underwent R0 curative resection was reported to range from 21% to 69%, and 0% for patients who did not undergo R0 resection. Thus, achieving a complete resection and obtaining negative margins (R0 resection) is important in the surgical management of GBC. [17,18] In our case, an extended right hepatic lobectomy was performed, due to GBC with invasion of the liver and right main portal vein thrombosis. In the past, the role of adjuvant therapy in the treatment of GBC was unclear. However, since 2004, 4 retrospective reports have shown that adjuvant therapy for advanced GBC can significantly improve overall survival. [19-22] Adjuvant chemoradiation therapy is recommended for lymph node-positive GBC or T2/T3 GBC with unknown lymph node status after surgical resection. [23,24] In addition, chemotherapy with or without radiotherapy is administered according to the patient's general condition. Chemoradiation therapy is administered on the premise that the general condition of patients with T2-3NxM0 stage is good. In patients with more advanced stages, radiotherapy cannot be administered. In our case, adjuvant therapy was, S-1 plus oxaliplatin (SOX) therapy which is used as neoadjuvant chemotherapy for gastric cancer and colorectal cancer. [19,25] Radiotherapy was not performed in our patient, who was at T4N0M0, IVA stage.

4. Conclusions

According to the above discussions, we can safely infer the following disease course in our case: gallbladder cancer cells migrated and invaded to the gallbladder bed in the liver, resulting in tumor growth in the liver and the cancer cells then grew in the lumen of the portal vein. Early diagnosis of GBC is difficult due to nonspecific symptoms; however, appropriate surgery and

adjuvant therapy can improve survival. Hence, this case provides a reminder for surgeons of the importance of early diagnosis, adequate surgical and adjuvant therapy in patients with GBC, especially tumor biomarker such as serum CA19–9 that play an important role in early diagnosis should be paid more attention.

Author contributions

Conceptualization: Xueli Bai. Data curation: Wei Chen. Formal analysis: Wei Chen.

Supervision: Xueli Bai, Tingbo Liang.

Visualization: Tingbo Liang.

Writing – original draft: Xiaozhen Zhang, Jianjun Tu, Tao Ma. Writing – review & editing: Xiaozhen Zhang, Xueli Bai.

References

- [1] Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 2014;6:99–109.
- [2] Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349–64.
- [3] Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: Geographical distribution and risk factors. Int J Cancer 2006;118:1591–602.
- [4] Batra S, Doval DC, Batra U, et al. Gallbladder cancer with tumor thrombus in the superior vena cava. Hepatobiliary Pancreat Dis Int 2010;9:325–8.
- [5] Basit SA, Stone CD, Gish R. Portal vein thrombosis. Clin Liver Dis 2015;19:199–221.
- [6] Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder. Lancet Oncol 2003;4:167–76.
- [7] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;67:93–9.
- [8] Uesaka K, Yasui K, Morimoto T, et al. Visualization of routes of lymphatic drainage of the gallbladder with a carbon particle suspension. J Am Coll Surg 1996;183:345–50.
- [9] Xin-Wei Y, Jue Y, Bao-Hua Z, et al. An unusual gallbladder carcinoma with tumor thrombus in the common bile duct. J Cancer Res Ther 2013;9:122–4.

- [10] Wang Y, Gu XD, Li ZY, et al. Gallbladder carcinosarcoma accompanied with bile duct tumor thrombi: a case report. Oncol Lett 2013;5:1809–12.
- [11] Midorikawa Y, Kubota K, Komatsu Y, et al. Gallbladder carcinoma with a tumor thrombus in the common bile duct: an unusual cause of obstructive jaundice. Surgery 2000;127:473–4.
- [12] Quirk M, Kim YH, Saab S, et al. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015;21:3462–71.
- [13] Kaneko T, Nakao A, Endo T, et al. Intraportal tumor thrombus of gallbladder carcinoma: detection with intravascular ultrasonography. Am J Gastroenterol 1996;91:1268–9.
- [14] Iyomasa S, Matsuzaki Y, Hiei K, et al. Adenosquamous carcinoma of the gallbladder with tumor thrombus in left portal trunk. J Hep Bil Pancr Surg 1997;4:332–6.
- [15] Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 2007;11:671–81.
- [16] Kim JH, Kim TK, Eun HW, et al. Preoperative evaluation of gallbladder carcinoma: efficacy of combined use of MR imaging, MR cholangiography, and contrast-enhanced dual-phase three-dimensional MR angiography. J Magn Reson Imaging 2002;16:676–84.
- [17] Bourros C, Gary M, Baldwin K, et al. Gallbladder cancer: past, present and an uncertain future. Surg Oncol 2012;21:e183–91.
- [18] Joo I, Lee JY, Kim JH, et al. Differentiation of adenomyomatosis of the gallbladder from early-stage, wall-thickening-type gallbladder cancer using high-resolution ultrasound. Eur Radiol 2013;23:730–8.
- [19] Aisu N, Yoshida Y, Komono A, et al. Perioperative chemotherapy with S-1 plus oxaliplatin (SOX) for stage III colorectal cancer patients. J Clin Oncol 2016;34(suppl):1.
- [20] Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol 2007;96:8–13.
- [21] Mayo SC, Shore AD, Nathan H, et al. National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. J Gastrointest Surg 2010;14:1578–91.
- [22] Mitin T, Enestvedt CK, Jemal A, et al. Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival. J Natl Cancer Inst 2017;109:djw324.
- [23] Cho SY, Kim SH, Park SJ, et al. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol 2010;102:87–93.
- [24] Hoehn RS, Wima K, Ertel AE, et al. Adjuvant therapy for gallbladder cancer: an analysis of the National Cancer Data Base. J Gastrointest Surg 2015;19:1794–801.
- [25] Zhong DT, Wu RP, Wang XL, et al. Combination chemotherapy with S-1 and oxaliplatin (SOX) as first-line treatment in elderly patients with advanced gastric cancer. Pathol Oncol Res 2015;21:867–73.